Viewing serine/threonine protein phosphatases through the eyes of drug designers

FEBS Journal

Volumn 280, Issue 19, 2013, Pages 4739-4760

  Zhang, Mengmeng ^a   Yogesha, S D ^a   Mayfield, Joshua E ^a   Gill, Gordon N ^b   Zhang, Yan ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

drug design; high throughput assay; serine threonine protein phosphatase; small molecule inhibitors; structure guided drug discovery

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; FOSTRIECIN; GUANABENZ; OKADAIC ACID; PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE 5; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN PHOSPHATASE 1 INHIBITOR; PROTEIN WIP1; RABEPRAZOLE; SALUBRINAL; SANGUINARINE; SERINE PROTEIN PHOSPHATASE; TACROLIMUS; THREONINE PROTEIN PHOSPHATASE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

BIOLOGICAL FUNCTIONS; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

DRUG DESIGN; HIGH THROUGHPUT ASSAY; SERINE/THREONINE PROTEIN PHOSPHATASE; SMALL MOLECULE INHIBITORS; STRUCTURE-GUIDED DRUG DISCOVERY;

ANIMALS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; PHOSPHOPROTEIN PHOSPHATASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EUKARYOTA;

EID: 84884595522     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12481     Document Type: Review

References (155)

1. Gunawardena J, (2005) Multisite protein phosphorylation makes a good threshold but can be a poor switch. Proc Natl Acad Sci U S A 102, 14617-14622.
2. Nagaraj N, Wisniewski JR, Geiger T, Cox J, Kircher M, Kelso J, Paabo S, &, Mann M, (2011) Deep proteome and transcriptome mapping of a human cancer cell line. Mol Syst Biol 7, 548.
3. Hunter T, (1995) Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 80, 225-236.
4. Novak B, Kapuy O, Domingo-Sananes MR, &, Tyson JJ, (2010) Regulated protein kinases and phosphatases in cell cycle decisions. Curr Opin Cell Biol 22, 801-808.
5. De Munter S, Kohn M, &, Bollen M, (2013) Challenges and opportunities in the development of protein phosphatase-directed therapeutics. ACS Chem Biol 8, 36-45.
6. Cohen P, (2002) Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 1, 309-315.
7. Kondapalli L, Soltani K, &, Lacouture ME, (2005) The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. J Am Acad Dermatol 53, 291-302.
8. Grant SK, (2009) Therapeutic protein kinase inhibitors. Cell Mol Life Sci 66, 1163-1177.
9. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, &, Mann M, (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-648.
10. Cohen P, (1992) Signal integration at the level of protein kinases, protein phosphatases and their substrates. Trends Biochem Sci 17, 408-413.
11. Mayer-Jaekel RE, &, Hemmings BA, (1994) Protein phosphatase 2A-a 'menage a trois'. Trends Cell Biol 4, 287-291.
12. Wurzenberger C, &, Gerlich DW, (2011) Phosphatases: providing safe passage through mitotic exit. Nat Rev Mol Cell Biol 12, 469-482.
13. Johnson ES, &, Kornbluth S, (2012) Phosphatases driving mitosis: pushing the gas and lifting the brakes. Prog Mol Biol Transl Sci 106, 327-341.
14. Mochida S, &, Hunt T, (2012) Protein phosphatases and their regulation in the control of mitosis. EMBO Rep 13, 197-203.
15. Ceulemans H, &, Bollen M, (2004) Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiol Rev 84, 1-39.
16. Kamenski T, Heilmeier S, Meinhart A, &, Cramer P, (2004) Structure and mechanism of RNA polymerase II CTD phosphatases. Mol Cell 15, 399-407.
17. Gallego M, &, Virshup DM, (2005) Protein serine/threonine phosphatases: life, death, and sleeping. Curr Opin Cell Biol 17, 197-202.
18. Alonso A, Sasin J, Bottini N, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, &, Mustelin T, (2004) Protein tyrosine phosphatases in the human genome. Cell 117, 699-711.
19. Yap TA, &, Workman P, (2012) Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol 52, 549-573.
20. Shi Y, (2009) Serine/threonine phosphatases: mechanism through structure. Cell 139, 468-484.
21. Das AK, Helps NR, Cohen PT, &, Barford D, (1996) Crystal structure of the protein serine/threonine phosphatase 2C at 2.0 A resolution. EMBO J 15, 6798-6809.
22. Belova GI, Demidov ON, Fornace AJ Jr, &, Bulavin DV, (2005) Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis. Cancer Biol Ther 4, 1154-1158.
23. Yamaguchi H, Durell SR, Feng H, Bai Y, Anderson CW, &, Appella E, (2006) Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1. Biochemistry 45, 13193-13202.
24. Swingle MR, Amable L, Lawhorn BG, Buck SB, Burke CP, Ratti P, Fischer KL, Boger DL, &, Honkanen RE, (2009) Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and (beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors. J Pharmacol Exp Ther 331, 45-53.
25. He R, Zeng LF, He Y, Zhang S, &, Zhang ZY, (2012) Small molecule tools for functional interrogation of protein tyrosine phosphatases. FEBS J 280, 731-750.
26. Allen KN, &, Dunaway-Mariano D, (2004) Phosphoryl group transfer: evolution of a catalytic scaffold. Trends Biochem Sci 29, 495-503.
27. Zhang M, Liu J, Kim Y, Dixon JE, Pfaff SL, Gill GN, Noel JP, &, Zhang Y, (2010) Structural and functional analysis of the phosphoryl transfer reaction mediated by the human small C-terminal domain phosphatase, Scp1. Protein Sci 19, 974-986.
28. Egloff S, &, Murphy S, (2008) Cracking the RNA polymerase II CTD code. Trends Genet 24, 280-288.
29. Archambault J, Chambers RS, Kobor MS, Ho Y, Cartier M, Bolotin D, Andrews B, Kane CM, &, Greenblatt J, (1997) An essential component of a C-terminal domain phosphatase that interacts with transcription factor IIF in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 94, 14300-14305.
30. Hausmann S, Koiwa H, Krishnamurthy S, Hampsey M, &, Shuman S, (2005) Different strategies for carboxyl-terminal domain (CTD) recognition by serine 5-specific CTD phosphatases. J Biol Chem 280, 37681-37688.
31. Yeo M, Lee SK, Lee B, Ruiz EC, Pfaff SL, &, Gill GN, (2005) Small CTD phosphatases function in silencing neuronal gene expression. Science 307, 596-600.
32. Visvanathan J, Lee S, Lee B, Lee JW, &, Lee SK, (2007) The microRNA miR-124 antagonizes the anti-neural REST/SCP1 pathway during embryonic CNS development. Genes Dev 21, 744-749.
33. Xue Y, Ouyang K, Huang J, Zhou Y, Ouyang H, Li H, Wang G, Wu Q, Wei C, Bi Y, et al,. (2013) Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated microRNA circuits. Cell 152, 82-96.
34. Cho EJ, Kobor MS, Kim M, Greenblatt J, &, Buratowski S, (2001) Opposing effects of Ctk1 kinase and Fcp1 phosphatase at Ser 2 of the RNA polymerase II C-terminal domain. Genes Dev 15, 3319-3329.
35. Hausmann S, &, Shuman S, (2002) Characterization of the CTD phosphatase Fcp1 from fission yeast. Preferential dephosphorylation of serine 2 versus serine 5. J Biol Chem 277, 21213-21220.
36. Yeo M, Lin PS, Dahmus ME, &, Gill GN, (2003) A novel RNA polymerase II C-terminal domain phosphatase that preferentially dephosphorylates serine 5. J Biol Chem 278, 26078-26085.
37. Ghosh A, Shuman S, &, Lima CD, (2008) The structure of Fcp1, an essential RNA polymerase II CTD phosphatase. Mol Cell 32, 478-490.
38. Zhang Y, Kim Y, Genoud N, Gao J, Kelly JW, Pfaff SL, Gill GN, Dixon JE, &, Noel JP, (2006) Determinants for dephosphorylation of the RNA polymerase II C-terminal domain by Scp1. Mol Cell 24, 759-770.
39. Zhang M, Gill GN, &, Zhang Y, (2010) Bio-molecular architects: a scaffold provided by the C-terminal domain of eukaryotic RNA polymerase II. Nano Rev 1, doi: 10.3402/nano.v1i0.5502.
40. Zhang M, Cho EJ, Burstein G, Siegel D, &, Zhang Y, (2011) Selective inactivation of a human neuronal silencing phosphatase by a small molecule inhibitor. ACS Chem Biol 6, 511-519.
41. Sapkota G, Knockaert M, Alarcon C, Montalvo E, Brivanlou AH, &, Massague J, (2006) Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways. J Biol Chem 281, 40412-40419.
42. Dai J, Zhang J, Sun Y, Wu Q, Sun L, Ji C, Gu S, Feng C, Xie Y, &, Mao Y, (2006) Characterization of a novel human protein phosphatase 2C family member, PP2Ckappa. Int J Mol Med 17, 1117-1123.
43. Lu X, Bocangel D, Nannenga B, Yamaguchi H, Appella E, &, Donehower LA, (2004) The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Mol Cell 15, 621-634.
44. Shreeram S, Demidov ON, Hee WK, Yamaguchi H, Onishi N, Kek C, Timofeev ON, Dudgeon C, Fornace AJ, Anderson CW, et al,. (2006) Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell 23, 757-764.
45. Lammers T, Peschke P, Ehemann V, Debus J, Slobodin B, Lavi S, &, Huber P, (2007) Role of PP2Calpha in cell growth, in radio- and chemosensitivity, and in tumorigenicity. Mol Cancer 6, 65.
46. Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O'Neill A, Castillo-Martin M, Nowak DG, Naguib A, Grace DM, et al,. (2011) Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 20, 173-186.
47. Warfel NA, &, Newton AC, (2012) Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling. J Biol Chem 287, 3610-3616.
48. Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, &, Donehower LA, (2008) The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 27, 123-135.
49. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, et al,. (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31, 210-215.
50. Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KC, Gabriele T, McCurrach ME, Marks JR, Hoey T, et al,. (2002) Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 31, 133-134.
51. Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA, Rao PH, Donehower LA, &, Kim JY, (2008) Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol 86, 245-256.
52. Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchio C, Geyer FC, Savage K, Parry S, et al,. (2009) PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 15, 2269-2280.
53. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T, &, Inazawa J, (2003) PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 63, 1876-1883.
54. Le Guezennec X, &, Bulavin DV, (2010) WIP1 phosphatase at the crossroads of cancer and aging. Trends Biochem Sci 35, 109-114.
55. Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, Appella E, &, Fornace AJ Jr, (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 36, 343-350.
56. Lu X, Ma O, Nguyen TA, Jones SN, Oren M, &, Donehower LA, (2007) The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 12, 342-354.
57. Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H, Taya Y, &, Imai K, (2000) p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 19, 6517-6526.
58. Vogt A, Tamewitz A, Skoko J, Sikorski RP, Giuliano KA, &, Lazo JS, (2005) The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J Biol Chem 280, 19078-19086.
59. Rogers JP, Beuscher AE, Flajolet M, McAvoy T, Nairn AC, Olson AJ, &, Greengard P, (2006) Discovery of protein phosphatase 2C inhibitors by virtual screening. J Med Chem 49, 1658-1667.
60. O'Neill AK, Niederst MJ, &, Newton AC, (2013) Suppression of survival signalling pathways by the phosphatase PHLPP. FEBS J 280, 572-583.
61. Sierecki E, Sinko W, McCammon JA, &, Newton AC, (2010) Discovery of small molecule inhibitors of the PH domain leucine-rich repeat protein phosphatase (PHLPP) by chemical and virtual screening. J Med Chem 53, 6899-6911.
62. Aburai N, Yoshida M, Ohnishi M, &, Kimura K, (2010) Sanguinarine as a potent and specific inhibitor of protein phosphatase 2C in vitro and induces apoptosis via phosphorylation of p38 in HL60 cells. Biosci Biotechnol Biochem 74, 548-552.
63. Swierczek K, Pandey AS, Peters JW, &, Hengge AC, (2003) A comparison of phosphonothioic acids with phosphonic acids as phosphatase inhibitors. J Med Chem 46, 3703-3708.
64. Lin YX, Xu WN, Liang LR, Pang BS, Nie XH, Zhang J, Wang H, Liu YX, Wang DQ, Xu ZY, et al,. (2009) The cross-sectional and longitudinal association of the BODE index with quality of life in patients with chronic obstructive pulmonary disease. Chin Med J (Engl) 122, 2939-2944.
65. Goldberg J, Huang HB, Kwon YG, Greengard P, Nairn AC, &, Kuriyan J, (1995) Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. Nature 376, 745-753.
66. Egloff MP, Cohen PT, Reinemer P, &, Barford D, (1995) Crystal structure of the catalytic subunit of human protein phosphatase 1 and its complex with tungstate. J Mol Biol 254, 942-959.
67. Tachibana K, Scheuer PJ, Tsukitani Y, Kikushi H, Engen DV, Clardy J, Gopichand Y, &, Schmitz FJ, (1981) Okadaic acid, a cytotoxic polyether from the marine sponges of the genus Halichondria. J Am Chem Soc 103, 2469-2471.
68. Bialojan C, &, Takai A, (1988) Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J 256, 283-290.
69. MacKintosh C, Beattie KA, Klumpp S, Cohen P, &, Codd GA, (1990) Cyanobacterial microcystin-LR is a potent and specific inhibitor of protein phosphatases 1 and 2A from both mammals and higher plants. FEBS Lett 264, 187-192.
70. Maynes JT, Bateman KS, Cherney MM, Das AK, Luu HA, Holmes CF, &, James MN, (2001) Crystal structure of the tumor-promoter okadaic acid bound to protein phosphatase-1. J Biol Chem 276, 44078-44082.
71. Swingle M, Ni L, &, Honkanen RE, (2007) Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol Biol 365, 23-38.
72. Xing Y, Xu Y, Chen Y, Jeffrey PD, Chao Y, Lin Z, Li Z, Strack S, Stock JB, &, Shi Y, (2006) Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins. Cell 127, 341-353.
73. Zhang Z, Zhao S, Long F, Zhang L, Bai G, Shima H, Nagao M, &, Lee EY, (1994) A mutant of protein phosphatase-1 that exhibits altered toxin sensitivity. J Biol Chem 269, 16997-17000.
74. Zhang L, Zhang Z, Long F, &, Lee EY, (1996) Tyrosine-272 is involved in the inhibition of protein phosphatase-1 by multiple toxins. Biochemistry 35, 1606-1611.
75. Botes D, Tuinman A, Wessels P, Viljoen C, Kruger H, Williams DH, Santikam S, Smith R, &, Hammond SJ, (1984) The structure of cyanoginosin-LA, a cyclic heptapeptide toxin from the cyanobacterium Microcystis aeruginosa. J Chem Soc Perkin Trans 1, 2311-2318.
76. Honkanen RE, Zwiller J, Moore RE, Daily SL, Khatra BS, Dukelow M, &, Boynton AL, (1990) Characterization of microcystin-LR, a potent inhibitor of type 1 and type 2A protein phosphatases. J Biol Chem 265, 19401-19404.
77. Yoshizawa S, Matsushima R, Watanabe MF, Harada K, Ichihara A, Carmichael WW, &, Fujiki H, (1990) Inhibition of protein phosphatases by microcystins and nodularin associated with hepatotoxicity. J Cancer Res Clin Oncol 116, 609-614.
78. Craig M, Luu HA, McCready TL, Williams D, Andersen RJ, &, Holmes CF, (1996) Molecular mechanisms underlying the interaction of motuporin and microcystins with type-1 and type-2A protein phosphatases. Biochem Cell Biol 74, 569-578.
79. MacKintosh RW, Dalby KN, Campbell DG, Cohen PT, Cohen P, &, MacKintosh C, (1995) The cyanobacterial toxin microcystin binds covalently to cysteine-273 on protein phosphatase 1. FEBS Lett 371, 236-240.
80. Zhang Z, Zhao S, Deans-Zirattu S, Bai G, &, Lee EY, (1993) Mutagenesis of the catalytic subunit of rabbit muscle protein phosphatase-1. Mol Cell Biochem 127-128, 113-119.
81. Kita A, Matsunaga S, Takai A, Kataiwa H, Wakimoto T, Fusetani N, Isobe M, &, Miki K, (2002) Crystal structure of the complex between calyculin A and the catalytic subunit of protein phosphatase 1. Structure 10, 715-724.
82. Maynes JT, Luu HA, Cherney MM, Andersen RJ, Williams D, Holmes CF, &, James MN, (2006) Crystal structures of protein phosphatase-1 bound to motuporin and dihydromicrocystin-LA: elucidation of the mechanism of enzyme inhibition by cyanobacterial toxins. J Mol Biol 356, 111-120.
83. Kelker MS, Page R, &, Peti W, (2009) Crystal structures of protein phosphatase-1 bound to nodularin-R and tautomycin: a novel scaffold for structure-based drug design of serine/threonine phosphatase inhibitors. J Mol Biol 385, 11-21.
84. Huhn J, Jeffrey PD, Larsen K, Rundberget T, Rise F, Cox NR, Arcus V, Shi Y, &, Miles CO, (2009) A structural basis for the reduced toxicity of dinophysistoxin-2. Chem Res Toxicol 22, 1782-1786.
85. Wells JA, &, McClendon CL, (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009.
86. Heroes E, Lesage B, Gornemann J, Beullens M, Van Meervelt L, &, Bollen M, (2013) The PP1 binding code: a molecular-lego strategy that governs specificity. FEBS J 280, 584-595.
87. Cohen PT, (2002) Protein phosphatase 1-targeted in many directions. J Cell Sci 115, 241-256.
88. Peti W, Nairn AC, &, Page R, (2013) Structural basis for protein phosphatase 1 regulation and specificity. FEBS J 280, 596-611.
89. Kolupaeva V, &, Janssens V, (2013) PP1 and PP2A phosphatases-cooperating partners in modulating retinoblastoma protein activation. FEBS J 280, 627-643.
90. Bollen M, Peti W, Ragusa MJ, &, Beullens M, (2010) The extended PP1 toolkit: designed to create specificity. Trends Biochem Sci 35, 450-458.
91. Choy MS, Page R, &, Peti W, (2012) Regulation of protein phosphatase 1 by intrinsically disordered proteins. Biochem Soc Trans 40, 969-974.
92. Terrak M, Kerff F, Langsetmo K, Tao T, &, Dominguez R, (2004) Structural basis of protein phosphatase 1 regulation. Nature 429, 780-784.
93. Pinheiro AS, Marsh JA, Forman-Kay JD, &, Peti W, (2011) Structural signature of the MYPT1-PP1 interaction. J Am Chem Soc 133, 73-80.
94. Ragusa MJ, Dancheck B, Critton DA, Nairn AC, Page R, &, Peti W, (2010) Spinophilin directs protein phosphatase 1 specificity by blocking substrate binding sites. Nat Struct Mol Biol 17, 459-464.
95. Ragusa MJ, Allaire M, Nairn AC, Page R, &, Peti W, (2011) Flexibility in the PP1:spinophilin holoenzyme. FEBS Lett 585, 36-40.
96. Dancheck B, Ragusa MJ, Allaire M, Nairn AC, Page R, &, Peti W, (2011) Molecular investigations of the structure and function of the protein phosphatase 1-spinophilin-inhibitor 2 heterotrimeric complex. Biochemistry 50, 1238-1246.
97. O'Connell N, Nichols SR, Heroes E, Beullens M, Bollen M, Peti W, &, Page R, (2012) The molecular basis for substrate specificity of the nuclear NIPP1:PP1 holoenzyme. Structure 20, 1746-1756.
98. Egloff MP, Johnson DF, Moorhead G, Cohen PT, Cohen P, &, Barford D, (1997) Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1. EMBO J 16, 1876-1887.
99. Tappan E, &, Chamberlin AR, (2008) Activation of protein phosphatase 1 by a small molecule designed to bind to the enzyme's regulatory site. Chem Biol 15, 167-174.
100. Ammosova T, Platonov M, Yedavalli VR, Obukhov Y, Gordeuk VR, Jeang KT, Kovalskyy D, &, Nekhai S, (2012) Small molecules targeted to a non-catalytic 'RVxF' binding site of protein phosphatase-1 inhibit HIV-1. PLoS ONE 7, e39481.
101. Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, Kaufman RJ, Ma D, Coen DM, Ron D, et al,. (2005) A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 307, 935-939.
102. Tsaytler P, Harding HP, Ron D, &, Bertolotti A, (2011) Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science 332, 91-94.
103. Janssens V, &, Goris J, (2001) Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353, 417-439.
104. Janssens V, &, Rebollo A, (2012) The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr Mol Med 12, 268-287.
105. Sablina AA, Hector M, Colpaert N, &, Hahn WC, (2010) Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res 70, 10474-10484.
106. Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, &, Terro F, (2012) Tau protein phosphatases in Alzheimer's disease: the leading role of PP2A. Ageing Res Rev 12, 39-49.
107. Nagao M, Sakai R, Kitagawa Y, Ikeda I, Sasaki K, Shima H, &, Sugimura T, (1989) Role of protein phosphatases in malignant transformation. Princess Takamatsu Symp 20, 177-184.
108. Ruediger R, Pham HT, &, Walter G, (2001) Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. Oncogene 20, 10-15.
109. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, &, Vitek MP, (2011) Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 30, 2504-2513.
110. von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, &, Grosveld G, (1992) Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: characterization of the set gene. Mol Cell Biol 12, 3346-3355.
111. Li M, Makkinje A, &, Damuni Z, (1996) The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 271, 11059-11062.
112. Dobrowsky RT, Kamibayashi C, Mumby MC, &, Hannun YA, (1993) Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem 268, 15523-15530.
113. Nagahara Y, Matsuoka Y, Saito K, Ikekita M, Higuchi S, &, Shinomiya T, (2001) Coordinate involvement of cell cycle arrest and apoptosis strengthen the effect of FTY720. Jpn J Cancer Res 92, 680-687.
114. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et al,. (2007) CIP2A inhibits PP2A in human malignancies. Cell 130, 51-62.
115. Mochida S, Maslen SL, Skehel M, &, Hunt T, (2010) Greatwall phosphorylates an inhibitor of protein phosphatase 2A that is essential for mitosis. Science 330, 1670-1673.
116. Gharbi-Ayachi A, Labbe JC, Burgess A, Vigneron S, Strub JM, Brioudes E, Van-Dorsselaer A, Castro A, &, Lorca T, (2010) The substrate of Greatwall kinase, Arpp 19, controls mitosis by inhibiting protein phosphatase 2A. Science 330, 1673-1677.
117. Walsh AH, Cheng A, &, Honkanen RE, (1997) Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Lett 416, 230-234.
118. Lewy DS, Gauss CM, Soenen DR, &, Boger DL, (2002) Fostriecin: chemistry and biology. Curr Med Chem 9, 2005-2032.
119. Honkanen RE, (2005) Serine/threonine protein phosphatase inhibitors with anti-tumor activity. Handbk Exp Pharm 167, 295-317.
120. de Jong RS, de Vries EG, &, Mulder NH, (1997) Fostriecin: a review of the preclinical data. Anticancer Drugs 8, 413-418.
121. Buck SB, Hardouin C, Ichikawa S, Soenen DR, Gauss CM, Hwang I, Swingle MR, Bonness KM, Honkanen RE, &, Boger DL, (2003) Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibition. J Am Chem Soc 125, 15694-15695.
122. Le LH, Erlichman C, Pillon L, Thiessen JJ, Day A, Wainman N, Eisenhauer EA, &, Moore MJ, (2004) Phase I and pharmacokinetic study of fostriecin given as an intravenous bolus daily for five consecutive days. Invest New Drugs 22, 159-167.
123. Gehringer MM, (2004) Microcystin-LR and okadaic acid-induced cellular effects: a dualistic response. FEBS Lett 557, 1-8.
124. Falconer IR, &, Humpage AR, (2001) Preliminary evidence for in vivo tumour initiation by oral administration of extracts of the blue-green alga Cylindrospermopsis raciborskii containing the toxin cylindrospermopsin. Environ Toxicol 16, 192-195.
125. Yatsunami J, Komori A, Ohta T, Suganuma M, Yuspa SH, &, Fujiki H, (1993) Hyperphosphorylation of cytokeratins by okadaic acid class tumor promoters in primary human keratinocytes. Cancer Res 53, 992-996.
126. Rossini GP, Sgarbi N, &, Malaguti C, (2001) The toxic responses induced by okadaic acid involve processing of multiple caspase isoforms. Toxicon 39, 763-770.
127. Rusnak F, &, Mertz P, (2000) Calcineurin: form and function. Physiol Rev 80, 1483-1521.
128. Borel JF, Feurer C, Gubler HU, &, Stahelin H, (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6, 468-475.
129. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, &, Imanaka H, (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 40, 1249-1255.
130. Di Padova FE, (1994) Pharmacology of CsA and FK-506. Perspectives Drug Discovery Design 2, 49-56.
131. Griffith JP, Kim JL, Kim EE, Sintchak MD, Thomson JA, Fitzgibbon MJ, Fleming MA, Caron PR, Hsiao K, &, Navia MA, (1995) X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 82, 507-522.
132. Huai Q, Kim HY, Liu Y, Zhao Y, Mondragon A, Liu JO, &, Ke H, (2002) Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc Natl Acad Sci U S A 99, 12037-12042.
133. Jin L, &, Harrison SC, (2002) Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc Natl Acad Sci U S A 99, 13522-13526.
134. Grigoriu S, Bond R, Cossio P, Chen JA, Ly N, Hummer G, Page R, Cyert MS, &, Peti W, (2013) The molecular mechanism of substrate engagement and immunosuppressant inhibition of calcineurin. PLoS Biol 11, e1001492.
135. Nolan GP, (1994) NF-AT-AP-1 and Rel-bZIP: hybrid vigor and binding under the influence. Cell 77, 795-798.
136. Jain J, McCaffrey PG, Miner Z, Kerppola TK, Lambert JN, Verdine GL, Curran T, &, Rao A, (1993) The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 365, 352-355.
137. Li-Weber M, &, Krammer PH, (2003) Regulation of IL4 gene expression by T cells and therapeutic perspectives. Nat Rev Immunol 3, 534-543.
138. Jain AB, &, Fung JJ, (1996) Cyclosporine and tacrolimus in clinical transplant: a comparative review. Clin Immunother 5, 351-373.
139. Dumont FJ, (2000) FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem 7, 731-748.
140. Roehrl MH, Kang S, Aramburu J, Wagner G, Rao A, &, Hogan PG, (2004) Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc Natl Acad Sci U S A 101, 7554-7559.
141. McConnell JL, &, Wadzinski BE, (2009) Targeting protein serine/threonine phosphatases for drug development. Mol Pharmacol 75, 1249-1261.
142. Golden T, Swingle M, &, Honkanen RE, (2008) The role of serine/threonine protein phosphatase type 5 (PP5) in the regulation of stress-induced signaling networks and cancer. Cancer Metastasis Rev 27, 169-178.
143. Zhang J, Bao S, Furumai R, Kucera KS, Ali A, Dean NM, &, Wang XF, (2005) Protein phosphatase 5 is required for ATR-mediated checkpoint activation. Mol Cell Biol 25, 9910-9919.
144. Kang Y, Lee JH, Hoan NN, Sohn HM, Chang IY, &, You HJ, (2009) Protein phosphatase 5 regulates the function of 53BP1 after neocarzinostatin-induced DNA damage. J Biol Chem 284, 9845-9853.
145. Chen MS, Silverstein AM, Pratt WB, &, Chinkers M, (1996) The tetratricopeptide repeat domain of protein phosphatase 5 mediates binding to glucocorticoid receptor heterocomplexes and acts as a dominant negative mutant. J Biol Chem 271, 32315-32320.
146. Ramsey AJ, Russell LC, &, Chinkers M, (2009) C-terminal sequences of hsp70 and hsp90 as non-specific anchors for tetratricopeptide repeat (TPR) proteins. Biochem J 423, 411-419.
147. Prickett TD, &, Brautigan DL, (2006) The alpha4 regulatory subunit exerts opposing allosteric effects on protein phosphatases PP6 and PP2A. J Biol Chem 281, 30503-30511.
148. Huang X, &, Honkanen RE, (1998) Molecular cloning, expression, and characterization of a novel human serine/threonine protein phosphatase, PP7, that is homologous to Drosophila retinal degeneration C gene product (rdgC). J Biol Chem 273, 1462-1468.
149. Ishihara H, Martin BL, Brautigan DL, Karaki H, Ozaki H, Kato Y, Fusetani N, Watabe S, Hashimoto K, Uemura D, et al,. (1989) Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem Biophys Res Commun 159, 871-877.
150. Hori M, Magae J, Han YG, Hartshorne DJ, &, Karaki H, (1991) A novel protein phosphatase inhibitor, tautomycin. Effect on smooth muscle. FEBS Lett 285, 145-148.
151. Fruman DA, Bierer BE, Benes JE, Burakoff SJ, Austen KF, &, Katz HR, (1995) The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. J Immunol 154, 1846-1851.
152. 2+/calmodulin-dependent protein phosphatase and secretion in pancreatic acinar cells. J Biol Chem 269, 15111-15117.
153. Xu Z, Cetin B, Anger M, Cho US, Helmhart W, Nasmyth K, &, Xu W, (2009) Structure and function of the PP2A-Shugshugoshin interaction. Mol Cell 35, 426-441.
154. Kissinger CR, Parge HE, Knighton DR, Lewis CT, Pelletier LA, Tempczyk A, Kalish VJ, Tucker KD, Showalter RE, Moomaw EW, et al,. (1995) Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature 378, 641-644.
155. Bertini I, Calderone V, Fragai M, Luchinat C, &, Talluri E, (2009) Structural basis of serine/threonine phosphatase inhibition by the archetypal small molecules cantharidin and norcantharidin. J Med Chem 52, 4838-4843.